Pharmaceuticals, Biotechnology and Life Sciences
With Biotest-developed Yimmugo, Grifols adds to its remarkable franchise of intravenous and subcutaneous immunoglobulins to meet strong demand Yimmugo, already…
KINCRAIG, Scotland, June 17, 2024 (GLOBE NEWSWIRE) — Frontier Science Scotland (FSS), a leading contract clinical research organisation, advancing drug…
R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support…
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating…
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71%…
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses…
Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m1) will open on 19 June 2024 and close…
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) — Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering…